Q1 Earnings Estimate for AC Immune Issued By HC Wainwright

AC Immune (NASDAQ:ACIU) – Equities research analysts at HC Wainwright issued their Q1 2027 EPS estimates for AC Immune in a research note issued on Thursday, November 5th. HC Wainwright analyst A. Ghosh expects that the company will post earnings per share of $0.06 for the quarter. HC Wainwright currently has a “Strong-Buy” rating on the stock. The consensus estimate for AC Immune’s current full-year earnings is ($0.60) per share. HC Wainwright also issued estimates for AC Immune’s Q2 2027 earnings at $0.06 EPS, Q3 2027 earnings at $0.14 EPS and Q4 2027 earnings at $0.17 EPS.

AC Immune (NASDAQ:ACIU) last posted its earnings results on Wednesday, November 4th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.02. AC Immune had a negative net margin of 181.38% and a negative return on equity of 97.79%. The company had revenue of $3.88 million during the quarter, compared to the consensus estimate of $1.62 million.

ACIU has been the subject of a number of other reports. BTIG Research reissued a “buy” rating and set a $8.00 price objective on shares of AC Immune in a report on Wednesday, September 23rd. Zacks Research lowered AC Immune from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 28th. Finally, Weiss Ratings raised AC Immune from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, AC Immune presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

AC Immune Stock Performance

ACIU stock opened at $2.11 on Friday. The company has a market capitalization of $214.73 million, a P/E ratio of -4.22 and a beta of 1.64. AC Immune has a 52-week low of $2.02 and a 52-week high of $3.90. The business has a 50-day simple moving average of $2.55 and a two-hundred day simple moving average of $2.70.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. AXQ Capital LP purchased a new stake in AC Immune in the 2nd quarter valued at about $25,000. Dimensional Fund Advisors LP lifted its position in shares of AC Immune by 82.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 390,165 shares of the company’s stock worth $1,071,000 after buying an additional 176,701 shares in the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of AC Immune by 8.0% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 405,658 shares of the company’s stock worth $1,116,000 after buying an additional 30,035 shares in the last quarter. 51.36% of the stock is currently owned by hedge funds and other institutional investors.

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, focused on developing treatments and diagnostic products for neurodegenerative diseases. Its research primarily addresses Alzheimer’s disease, Parkinson’s disease and related disorders by targeting proteins believed to contribute to disease progression, including amyloid and tau.

The company’s technology platforms include SupraAntigen, which supports the discovery of antibodies and vaccines, and Morphomer, which is used to identify small-molecule compounds that may prevent or modify the abnormal aggregation of disease-associated proteins.